Apellis Pharmaceuticals Inc (NAS:APLS)
$ 28.075 -0.485 (-1.7%) Market Cap: 3.49 Bil Enterprise Value: 3.59 Bil PE Ratio: 0 PB Ratio: 12.94 GF Score: 42/100

Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 03:50PM GMT
Release Date Price: $55.02 (-2.24%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Apellis. And speaking on behalf of the company, we have CEO, Cedric Francois.

Before I turn it over to Cedric, just wanted to highlight for those on the webcast, you can submit a question using the ask-a-question feature in the portal, and I'm happy to ask a question on your behalf.

With that, I'll turn it over to Cedric. Cedric?

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you so much, Anupam, and what a pleasure to present again at the JPMorgan conference this year, obviously, under very different circumstances. But thank you for all of those attending virtually to the presentation on our company.

On Slide #2 -- all right, I'm having some technical issues here. But on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot